Benzinga | Apr 30, 2021 12:21PM EDT

RBC Capital Initiates Coverage On Nurix Therapeutics with Outperform Rating, Announces Price Target of $42

RBC Capital analyst Kennen MacKay initiates coverage on Nurix Therapeutics (NASDAQ:NRIX) with a Outperform rating and announces Price Target of $42.